title: N-acetyl serotonin derivatives as potent neuroprotectants for retinas.
abstract: N-acetylserotonin (NAS) is synthesized from serotonin by arylalkylamine N-acetyltransferase (AANAT), which is predominantly expressed in the pineal gland and retina. NAS activates TrkB in a circadian manner and exhibits antidepressant effects in a TrkB-dependent manner. It also enhances neurogenesis in hippocampus in sleep-deprived mice. Here we report the identification of NAS derivatives that possess much more robust neurotrophic effects with improved pharmacokinetic profiles. The compound N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC) selectively activates TrkB receptor with greater potency than NAS. It potently protects retinas from light-induced retinal degeneration (LIRD), which is tightly coupled with pronounced TrkB activation in retinas. Pharmacokinetic studies demonstrate that this compound is stable in serum and liver microsomes. It can pass the blood-brain barrier and blood-retinal barrier. Hence, HIOC is a good lead compound for further drug development for treating retinal degenerative diseases.
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors.forename: Jianying
authors.initials: J
authors.lastname: Shen
authors.forename: Kanika
authors.initials: K
authors.lastname: Ghai
authors.forename: Pradoldej
authors.initials: P
authors.lastname: Sompol
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.forename: Xuebing
authors.initials: X
authors.lastname: Cao
authors.forename: P Michael
authors.initials: PM
authors.lastname: Iuvone
authors.forename: Keqiang
authors.initials: K
authors.lastname: Ye
mesh_terms: D000263:Adenylate Kinase / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier; D001813:Blood-Retinal Barrier; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology; D002478:Cells, Cultured / Q000187:drug effects; D002540:Cerebral Cortex / Q000166:cytology; D004353:Drug Evaluation, Preclinical; D006207:Half-Life; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D009474:Neurons / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects / Q000528:radiation effects; D010880:Piperidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011499:Protein Processing, Post-Translational / Q000187:drug effects / Q000528:radiation effects; D051381:Rats; D020813:Receptor, trkB / Q000819:agonists*; D012160:Retina / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects / Q000528:radiation effects; D014018:Tissue Distribution
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D007211:Indoles; C571735:N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)-2-oxopiperidine-3-carboxamide; D018696:Neuroprotective Agents; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D020813:Receptor, trkB; D000263:Adenylate Kinase; C110939:adenylate kinase 1